XTLB
XTL Biopharmaceuticals Ltd. (NASDAQ)
Healthcare — Biotechnology
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Price History
Fundamentals
| Market Cap | $5.68M |
| P/E Ratio (TTM) | - |
| Forward P/E | - |
| EPS (TTM) | $-0.36 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -29.30% |
| Debt/Equity | - |
| Recommendation | None |
| Analyst Target | - |
| Analysts | - |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 51.5 |
| Beta | - |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $10.28 |
| 52-Week Low | $2.01 |
| 50-Day Avg | $2.61 |
| 200-Day Avg | $3.36 |
| Avg Volume | $2.01M |
| Volume | 7.4K |
Performance Analysis
NEUTRALXTLB presents a mixed picture with both positive and negative indicators.
Recent News
Last updated: Jul 02, 2026 13:38 UTC
Back to Screener Export Report